Viviane Santana da Silva
Research Subjects
Viviane Santana da Silva has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Samantha Neves
Santa Casa de Sao Paulo School of Medical Sciences
2 shared publications - Alexia Paganotti
Santa Casa de São Paulo School of Medical Sciences, São Paulo, SP, Brazil
1 shared publication - Ariadne Ribeiro Negrão
Vascular Surgery Department, Faculdade de Ciências Médicas da Santa Casa de São Paulo
1 shared publication - Camilla Moreira Ribeiro
Science Valley Research Institute
1 shared publication - Caroline Candida Carvalho de Oliveira
Vascular Surgery Department, Faculdade de Ciências Médicas da Santa Casa de São Paulo
1 shared publication - Eduardo Ramacciotti
Science Valley Research Institute, Brasil; Loyola University Medical Center, EUA
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 25, e20250065
Topical oxybutynin antiperspirant for axillary hyperhidrosis: a phase IIb PROBE design clinical trial (TODAY trial)
Background Primary hyperhidrosis is a chronic condition with limited therapeutic options. Objectives To evaluate the impact of 10% oxybutynin spray on axillary hyperhidrosis, considering both its local and systemic effects, in terms of Hyperhidrosis Disease Severity Scale (HDSS) outcomes for hyperhidrosis of the axilla and eight additional sites. Methods Prospective phase II PROBE design trial. Adult patients with axillary hyperhidrosis were randomized to receive a 10% oxybutynin topical spray, oral oxybutynin, or placebo spray for 35 days. Efficacy was evaluated on day 35 using the HDSS and a hyperhidrosis-specific quality-of-life (QoL) assessment questionnaire. Results 17 patients were randomized. No significant differences were observed in HDSS outcomes from baseline to day 35 in any of the three groups (2.5 [2 - 4], 4 [3 - 4], 3.5 [3 - 4], p= 0.207), although a trend to improvement was noted in both treatment groups. Significant improvement in the QoL questionnaire was observed from baseline to day 35 in the oxybutynin spray group (pre-intervention QoL: 78.5 [70 - 96] and post-intervention QoL: 38.5 [32 - 67], p = 0.031). Conclusions No differences were observed in the primary outcome. A significant improvement from baseline to day 35 was observed in the QoL questionnaire score for the oxybutynin spray group.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 25, e20250065
Open AccessTopical oxybutynin antiperspirant for axillary hyperhidrosis: a phase IIb PROBE design clinical trial (TODAY trial)
Background Primary hyperhidrosis is a chronic condition with limited therapeutic options. Objectives To evaluate the impact of 10% oxybutynin spray on axillary hyperhidrosis, considering both its local and systemic effects, in terms of Hyperhidrosis Disease Severity Scale (HDSS) outcomes for hyperhidrosis of the axilla and eight additional sites. Methods Prospective phase II PROBE design trial. Adult patients with axillary hyperhidrosis were randomized to receive a 10% oxybutynin topical spray, oral oxybutynin, or placebo spray for 35 days. Efficacy was evaluated on day 35 using the HDSS and a hyperhidrosis-specific quality-of-life (QoL) assessment questionnaire. Results 17 patients were randomized. No significant differences were observed in HDSS outcomes from baseline to day 35 in any of the three groups (2.5 [2 - 4], 4 [3 - 4], 3.5 [3 - 4], p= 0.207), although a trend to improvement was noted in both treatment groups. Significant improvement in the QoL questionnaire was observed from baseline to day 35 in the oxybutynin spray group (pre-intervention QoL: 78.5 [70 - 96] and post-intervention QoL: 38.5 [32 - 67], p = 0.031). Conclusions No differences were observed in the primary outcome. A significant improvement from baseline to day 35 was observed in the QoL questionnaire score for the oxybutynin spray group.
- 4 September 2025
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 41 (5) , 410-418
Transdermal radiofrequency (V ERASER®) plus polidocanol sclerotherapy versus polidocanol sclerotherapy alone for the treatment of reticular veins and telangiectasias. A randomized controlled trial (TYPER trial)
Background: Sclerotherapy with polidocanol is the gold standard treatment for telangiectasias and varicose veins, but technologies such as transdermal radiofrequency are also available. Transdermal radiofrequency (V Eraser ®) , a device that combines transdermal radiofrequency and sclerotherapy, was developed to treat these conditions. Methods: This was a prospective, randomized, and comparative study between transdermal radiofrequency and sclerotherapy for treating telangiectasias and reticular veins. Forty-one patients were randomized to either transdermal radiofrequency plus polidocanol sclerotherapy or polidocanol sclerotherapy alone and underwent a single treatment session. Efficacy was assessed using vessel clearance analysis in pre- and post-treatment images and the Aberdeen Varicose Vein Questionnaire. Results: Forty-six patients were enrolled. Both treatments significantly reduced vessel length in a single session ( p < .001). Sclerotherapy showed an average reduction of 30.7%, while transdermal radiofrequency reduced it by 33%, with no statistically significant difference ( p = .596). Quality of life improved, with pain reduction in 40% and 55% of patients in the right and left lower limbs, respectively ( p = .030 and p = .002). Conclusion: Transdermal radiofrequency was not superior to standard of care polidocanol sclerotherapy. Both methods improved quality of life, particularly in reducing pain associated with varicose veins.
- 4 September 2025
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 41 (5) , 410-418
Transdermal radiofrequency (V ERASER®) plus polidocanol sclerotherapy versus polidocanol sclerotherapy alone for the treatment of reticular veins and telangiectasias. A randomized controlled trial (TYPER trial)
Background: Sclerotherapy with polidocanol is the gold standard treatment for telangiectasias and varicose veins, but technologies such as transdermal radiofrequency are also available. Transdermal radiofrequency (V Eraser ®) , a device that combines transdermal radiofrequency and sclerotherapy, was developed to treat these conditions. Methods: This was a prospective, randomized, and comparative study between transdermal radiofrequency and sclerotherapy for treating telangiectasias and reticular veins. Forty-one patients were randomized to either transdermal radiofrequency plus polidocanol sclerotherapy or polidocanol sclerotherapy alone and underwent a single treatment session. Efficacy was assessed using vessel clearance analysis in pre- and post-treatment images and the Aberdeen Varicose Vein Questionnaire. Results: Forty-six patients were enrolled. Both treatments significantly reduced vessel length in a single session ( p < .001). Sclerotherapy showed an average reduction of 30.7%, while transdermal radiofrequency reduced it by 33%, with no statistically significant difference ( p = .596). Quality of life improved, with pain reduction in 40% and 55% of patients in the right and left lower limbs, respectively ( p = .030 and p = .002). Conclusion: Transdermal radiofrequency was not superior to standard of care polidocanol sclerotherapy. Both methods improved quality of life, particularly in reducing pain associated with varicose veins.